Epilepsy Multiplatform Variant Prediction (EpiMVP) - Admin Core

癫痫多平台变异预测(EpiMVP)管理核心的总体任务是监督 和协调EpiMVP无壁中心(CWow)的活动，包括基因和 变种癫痫核心(GVCC)、人类癫痫工具核心(HETC)、三个科学项目以及 中心范围内的有关计划章程、出版物、数据共享、与科学研究机构的沟通等事项 和世俗社区，以及伦理/法律问题。行政核心的首席调查员/主任， Lori Isom博士和Jack Parent博士有着成功的合作记录，他们协调 研究人员，同时进行多个项目，并传播研究结果，将提供 在拟建中心的五年内，全面领导EpiMVP。伊索姆博士和家长也将 担任EpiMVP指导委员会的联合主席，该委员会将由所有EpiMVP PIs和Core组成 董事(罗斯博士、王博士、卡维尔博士和乌勒博士)，并负责战略方向和 整个中心的业务活动。以密歇根大学为中心的EpiMVP项目 加州大学旧金山分校、西北大学、西澳大学和威尔·康奈尔大学 医学，由遗传学、临床护理、计算生物学、神经科学、 药理学和电生理学，处于癫痫研究的前沿，在 研究与发育性和癫痫性脑病及其他遗传性癫痫相关的基因变异。 许多调查人员之间存在着长期的、持续的合作。增加了三名调查人员 在癫痫领域，罗斯博士、施奈尔博士和白博士加强了Cow，并带来了新的视角 癫痫研究中的已知问题。由牛津大学为该组织提供的强有力的机构支持 MI医学院和MI大学药理学和神经病学系的形式 行政基础设施、规划拨款和学员支持进一步确保了这项工作的成功 求婚。EpiMVP管理核心寻求实现以下里程碑：1.提供 在EpiMVP的规划、开发、协调和整体管理方面具有领导力和专业知识。2. 监督CWW在其成员内的活动报告，并向NINDS报告和传播信息 从科学家到临床医生，再到患者和家庭，EpiMVP的研究结果吸引了广泛的支持者。3.至 帮助培训和指导下一代科学家，以促进对遗传疾病的理解和治疗 癫痫。EpiMVP行政核心的预期结果是：1)领导一个高效、 高效、协作的多机构CWow；2)EpiMVP成员之间的有效沟通 和NINDS，以及向研究界、医疗保健专业人员和 患者/家庭，3)下一代癫痫研究人员的培训和指导。

The overall mission of the Epilepsy Multiplatform Variant Prediction (EpiMVP) Administrative Core is to oversee and coordinate the activities of the EpiMVP Center Without Walls (CWOW), including the work of the Gene and Variant Curation Core (GVCC), the Human Epilepsy Tools Core (HETC), the three Scientific Projects, as well as center-wide matters related to the program charter, publications, data sharing, communications with the scientific and lay communities, and ethical/legal issues. The Administrative Core’s Principal Investigators (PIs)/Directors, Drs. Lori Isom and Jack Parent, who have a successful track record of working together, coordinating groups of investigators, conducting multiple projects simultaneously, and disseminating research findings, will provide overall leadership to EpiMVP throughout the five years of the proposed Center. Drs. Isom and Parent will also serve as Co-Chairs of the EpiMVP Steering Committee, which will be composed of all EpiMVP PIs and Core Directors (Dr. Ross, Dr. Wang, Dr. Carvill, and Dr. Uhler) and have responsibility for the strategic direction and operational activities of the entire Center. The EpiMVP Program, centered at the University of MI and reaching out to the University of CA-San Francisco, Northwestern University, the University of WA, and Weill Cornell Medicine, is composed of international experts in genetics, clinical care, computational biology, neuroscience, pharmacology, and electrophysiology who are at the forefront of epilepsy research with broad expertise in the study of gene variants linked to developmental and epileptic encephalopathies and other genetic epilepsies. Long-term, on-going collaborations are in place between many investigators. The addition of three investigators to the epilepsy field, Dr. Ross, Dr. Schnell, and Dr. Bai, strengthens the CWOW and brings a fresh perspective to known problems in epilepsy research. Strong institutional support, provided to the group by the University of MI Medical School and the University of MI Departments of Pharmacology and Neurology in the form of administrative infrastructure, planning grant funding, and trainee support, further insures the success of this proposal. The EpiMVP Administrative Core seeks to accomplish the following Milestones: 1. To provide leadership and expertise for the planning, development, coordination, and overall administration of EpiMVP. 2. To oversee reporting of CWOW activities within its membership and to NINDS and to disseminate information regarding EpiMVP findings to a broad constituency, from scientists to clinicians to patients and families. 3. To help train and mentor the next generation of scientists to advance the understanding and treatment of genetic epilepsies. The expected outcomes of the EpiMVP Administrative Core are: 1) Leadership of an efficient, productive, and collaborative multi-institutional CWOW; 2) Effective communication between EpiMVP members and NINDS, as well as rapid dissemination of results to the research community, healthcare professionals, and patients/families, 3) Training and mentoring of the next generation of epilepsy researchers.